Soluble syndecan-1 (sCD138) as a prognostic factor independent of mutation status in patients with chronic lymphocytic leukemia

International Journal of Laboratory Hematology
I JilaniMaher Albitar

Abstract

Syndecan-1 (sCD138) is a transmembrane heparan sulfate-bearing proteoglycan expressed in epithelial cells as well as hematopoietic cells that demonstrate plasmacytoid differentiation. Higher levels of sCD138 correlate with poor outcome in myeloma. We examined the association of circulating sCD138 levels in plasma with clinical behavior in 104 patients with chronic lymphocytic leukemia. sCD138 levels were significantly higher in patients (median, 52.8 ng/ml; range, 13.4-252.7 ng/ml) than in healthy control subjects (median, 19.86; range, 14.49-33.14 ng/ml) (P < 0.01). Elevated sCD138 (>median, 52.8 ng/ml) was associated with significantly shorter survival (P = 0.0004); this association was independent of IgVH mutation status, beta2-microglobulin (beta2-M) level, and treatment history. Patients with mutated IgVH but high sCD138 levels (>52.8 ng/ml) had significantly shorter survival than those with mutated IgVH and lower levels of sCD138. Similarly, patients with unmutated IgVH but high sCD138 levels had significantly shorter survival than those with lower sCD138 levels and unmutated IgVH (P = 0.007). In a multivariate Cox regression model, only Rai stage, beta2-M, and sCD138 remained predictors of survival. These data suggest th...Continue Reading

References

Jan 1, 1992·Annual Review of Cell Biology·M BernfieldE J Lose
Nov 1, 1989·Cell Regulation·R D SandersonM Bernfield
Aug 1, 1996·British Journal of Haematology·J WijdenesJ M Dore
Feb 21, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·A SebestyénL Kopper
Oct 27, 1999·Metabolism: Clinical and Experimental·A WangD M Templeton
Jun 29, 2000·Annual Review of Biochemistry·M BernfieldM Zako
Aug 10, 2000·British Journal of Haematology·M SutcliffeD H Wright
Apr 18, 2001·The Journal of Clinical Investigation·A Woods
May 2, 2003·The New England Journal of Medicine·Marta CrespoEmili Montserrat
Jun 16, 2004·European Journal of Cancer Care·A RedaelliC L Pashos
Oct 2, 2004·Oncology·Marja LeivonenCaj Haglund
Feb 25, 2005·The New England Journal of Medicine·Nicholas ChiorazziManlio Ferrarini
Aug 16, 2005·British Journal of Haematology·Richard LovellUNKNOWN Working Party on Leukaemia in Adults of the National Cancer Research Institute Haematological Oncology Clinical Studies Grou
Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander KröberStephan Stilgenbauer
Jan 25, 2006·Clinical and Laboratory Haematology·B SakaG Dinçol

❮ Previous
Next ❯

Citations

Mar 14, 2013·The FEBS Journal·Chun ShaoJoseph Zaia
Feb 25, 2017·Current Heart Failure Reports·Youn-Hyun KimW H Wilson Tang
Jun 23, 2018·British Journal of Pharmacology·Jessica Bertrand, Miriam Bollmann
Oct 15, 2011·Journal of Gynecologic Oncology·Yu Im KimSu Young Kim
May 3, 2019·Journal of Cellular Physiology·Tina VosoughiNajmaldin Saki
Jul 30, 2016·International Journal of Cancer. Journal International Du Cancer·Marine JaryDewi Vernerey
Jan 24, 2021·Cancer Treatment and Research Communications·Daniel Czarnowski
Apr 2, 2021·Seminars in Thrombosis and Hemostasis·Antonio Junior LepeddaMarilena Formato
Dec 16, 2020·Blood Reviews·Ishnoor SidhuAnilkumar Gopalakrishnapillai

❮ Previous
Next ❯

Related Concepts

Related Feeds

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.